Status:
COMPLETED
A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women
Lead Sponsor:
Pfizer
Conditions:
Endometriosis
Eligibility:
FEMALE
18-35 years
Phase:
PHASE1
Brief Summary
The study will investigate how well multiple doses of PF-02413873 are tolerated by healthy young women, how the body handles multiple doses of PF-02413873 and which effect PF-02413873 has on sex hormo...
Eligibility Criteria
Inclusion
- Healthy women of childbearing potential with a regular menstrual cycle
Exclusion
- Evidence or history of any major disease
- Pregnant or nursing women
- Requirement for chronic medication
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00800618
Start Date
November 1 2008
End Date
June 1 2009
Last Update
February 10 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
2
Pfizer Investigational Site
Overland Park, Kansas, United States, 66211
3
Pfizer Investigational Site
Overland Park, Kansas, United States, 66212
4
Pfizer Investigational Site
Brussels, Belgium, 1070